Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synmosa BiopharmaROCO:4114 -3.87%84 Gross Margin % is 42.11% as of Dec. 2025, which is 3% above its 10-year median of 40.69. GuruFocus rates ROCO:4114 with a GF Score™ of 84/100 and a GF Value™ of NT$33.93 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 941 Drug Manufacturers companies, Synmosa Biopharma ranks worse than 59.4% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Synmosa Biopharma had a gross margin of 42.11% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Synmosa Biopharma Gross Margin % Related Terms
Synmosa Biopharma Gross Margin % Historical Data
* Premium members only.
The historical data trend for Synmosa Biopharma's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Synmosa Biopharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synmosa Biopharma Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Synmosa Biopharma's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Synmosa Biopharma's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Synmosa Biopharma (ROCO:4114) has a Gross Margin % of 42.11% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Synmosa Biopharma and its competitors. This is near median its historical median of 40.69. Over the past decade, Synmosa Biopharma's Gross Margin % has ranged from 33.42 to 43.68. According to the industry distribution chart, Synmosa Biopharma ranks #559 out of 941 companies in the Drug Manufacturers industry, placing it in the top 59.4%.
Is Synmosa Biopharma's Gross Margin % too high?
Synmosa Biopharma's current Gross Margin % of 42.11% is near median its 10-year median of 40.69. Over the past 10 years, this metric has ranged from a low of 33.42 to a high of 43.68. The Drug Manufacturers industry median Gross Margin % is 48.54. Synmosa Biopharma's value of 42.11% is 13.2% below this industry median. Based on the distribution chart, Synmosa Biopharma ranks #559 out of 941 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Synmosa Biopharma has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Synmosa Biopharma's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Synmosa Biopharma ranks #559 out of 941 companies for Gross Margin %. This places Synmosa Biopharma in the lower half of its industry. The industry median Gross Margin % is 48.54. Synmosa Biopharma's value of 42.11% is 13.2% below this benchmark. Historically, Synmosa Biopharma's own Gross Margin % has ranged from 33.42 to 43.68 over the past decade. While the company's 10-year median is 40.69 vs. the industry median of 48.54, Synmosa Biopharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 941 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Synmosa Biopharma's current Gross Margin % of 42.11% is 13.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Synmosa Biopharma and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synmosa Biopharma's current Gross Margin % is 42.11%, which is near median its own 10-year median of 40.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synmosa Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Synmosa Biopharma (ROCO:4114) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$33.93, compared to a current price of NT$29.60 — trading 12.8% below its estimated fair value. The current Gross Margin % is 42.11%, which is near median its 10-year median of 40.69 and 13.2% below the Drug Manufacturers industry median of 48.54. Synmosa Biopharma's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Synmosa Biopharma (ROCO:4114), the current Gross Margin % is 42.11% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synmosa Biopharma (ROCO:4114) Overvalued in 2026?
Based on GuruFocus' analysis, Synmosa Biopharma stock appears to be undervalued.
The current stock price of NT$29.60 is trading 12.8% below its estimated GF Value™ of NT$33.93.
GuruFocus considers Synmosa Biopharma to be Modestly Undervalued.
Key valuation signals for ROCO:4114:
Gross Margin %: 42.11% (near median its 10-year median of 40.69)
GF Value™: NT$33.93 vs. price of NT$29.60 (12.8% below fair value)
Industry Position: 13.2% below the Drug Manufacturers median (#559 of 941)
No single metric tells the full story. See the ROCO:4114 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synmosa Biopharma Corp is engaged in pharmaceuticals and medical devices, cosmetics, animal drugs, chemical food additives, beverages manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. Its segments include the Active Pharmaceutical Ingredients segment and the Generic Drugs segment. The Generic Drugs segment derives the majority of the revenue.
84GF Score
Get the complete analysis for ROCO:4114
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4114 has been successfully added to your 
